Electrocoagulation

Mitsubishi Electric, ME Innovation Fund Invests in Hydroleap Pte. Ltd.

Retrieved on: 
Wednesday, July 19, 2023
Research, Professional Services, Hardware, Sustainability, Start-Up, Technology, Environment, Other Manufacturing, Green Technology, Science, Other Technology, Manufacturing, Mitsubishi Electric, Maintenance, China International Water & Electric Corporation, Water pollution, Sewage treatment, Electrocoagulation, Electro-oxidation

Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Hydroleap Pte.

Key Points: 
  • Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Hydroleap Pte.
  • Ltd., a Singapore-based startup company that provides the wastewater treatment solutions, as the fifth investment.
  • Southeast Asia, also known as the “factory of the world,” is facing a serious water pollution problems caused by industrial effluents.
  • To solve the industrial wastewater problems in Southeast Asia, Mitsubishi Electric and Hydroleap will work together to promote the widespread use of electrical wastewater treatment solutions.

NaturalShrimp, Inc. Signs Technology Licensing Agreement with Niterra Co., Ltd.

Retrieved on: 
Thursday, June 8, 2023
Food Tech, Retail, Technology, Agriculture, Natural Resources, Food, Beverage, Electrocoagulation, Aquaculture, NGK, OTCQB, Research, Hydrolastic, Nitrite, Animal, Investment, RAS, Ammonia, Water, Growth, Health, EC, Environment, Automation

The agreement allows for the trial use of NaturalShrimp’s patented shrimp growing technologies.

Key Points: 
  • The agreement allows for the trial use of NaturalShrimp’s patented shrimp growing technologies.
  • Niterra is a world leading maker of spark plugs for virtually every automotive, motorcycle, marine and small engine application.
  • Niterra Ventures Company, a division of Niterra Co., Ltd. actively explores opportunities to generate new revenue streams within various business sectors, including mobility, food, medical, energy and environment.
  • In line with this commitment, Niterra also possesses and operates a research facility dedicated to advancing the techniques and practices of shrimp cultivation.

NaturalShrimp Technologies Presented at Norwegian Tekna Aquaculture Conference

Retrieved on: 
Wednesday, November 30, 2022
Technology, Research, Biotechnology, Food, Beverage, Health, Retail, Food Tech, Other Science, Science, Farm, Proxy, Nitrite, Offshore aquaculture, Hydrolastic, Conference, Risk, Disruptive innovation, RAS, Disinfectant, Annual report, Prospectus, Electrocoagulation, Sale, Research, Health, OTCQB, Ammonia, Aquaculture, Animal, EC, Incorporated

NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), today announced its Electrocoagulation (EC) and Hydrogas technologies were showcased by its research partner Marineholmen RASLab at the Tekna Aquaculture Conference that took place November 23-24, 2022, in Trondheim, Norway.

Key Points: 
  • NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), today announced its Electrocoagulation (EC) and Hydrogas technologies were showcased by its research partner Marineholmen RASLab at the Tekna Aquaculture Conference that took place November 23-24, 2022, in Trondheim, Norway.
  • The 2022 Tekna Aquaculture Conference focused on sustainable fish welfare, a smaller environmental footprint, and a circular economy in the value chain.
  • NaturalShrimp partnered with Marineholmen RASLab to evaluate the effects of hyper-antioxidant technologies on oxidation and fish health in Recirculating Aquaculture Systems (RAS) and received initial positive trial results of its short-term validation study.
  • Tom Untermeyer, NaturalShrimp COO & CTO added, We thank Mark for including NaturalShrimp in his presentation to aquaculture industry experts in Norway.

The Worldwide Electrosurgery Industry is Expected to Reach $8.4 Billion by 2028 at a 5.9% CAGR - ResearchAndMarkets.com

Retrieved on: 
Friday, November 18, 2022
Health Technology, Health, Surgery, Lamina monopolar cell, Desiccation, Government, Bipolar, Electrocoagulation, Burns, Temperature, Dehydration, Defibrillation, Pain, Bleeding, Liver cancer, Critical care, Electrosurgery, Infection, Coagulation, Patient, Medical device, Medical imaging

The Global Electrosurgery Market size is expected to reach $8.4 billion by 2028, rising at a market growth of 5.9% CAGR during the forecast period.

Key Points: 
  • The Global Electrosurgery Market size is expected to reach $8.4 billion by 2028, rising at a market growth of 5.9% CAGR during the forecast period.
  • A high-frequency (radio frequency) alternating polarity electrical current is applied during electrosurgery to biological tissue to cut, coagulate, desiccate, or fulgurate tissue.
  • In hospital operating rooms or during outpatient treatments, electrosurgical devices are routinely utilized during surgical operations to assist prevent blood loss.
  • If sufficient precautions are not taken during the process, electrosurgery also carries a high risk of contamination.

Aesthetics Biomedical ® Inc. Announces FDA Clearance of Vivace Ultra™, The First-and-Only Personalized Radiofrequency (RF) Microneedling Technology

Retrieved on: 
Wednesday, October 19, 2022
Well, Physician, Dermatology, Female, Patient, HIPAA, Research, Technology, Electrocoagulation, Trial of the century, Marketing, MD, RF, Hemostasis, CEO, Dermis, Skin, Epidermis, FDA, Calibration, Lists of people executed in the United States, Male, Medical device, Medical imaging, RealSelf

PHOENIX, Oct. 19, 2022 /PRNewswire-PRWeb/ -- Today marks the beginning of (another) new era for Aesthetics Biomedical® Inc. Well-known for leading advancements in aesthetics technology, Aesthetics Biomedical's brand is committed to creation, distribution and marketing of novel aesthetic devices, products and services. Vivace Ultra™, the next generation and future of personalized aesthetics, has cleared the United States Food and Drug Administration (FDA) intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.

Key Points: 
  • Well-known for leading advancements in aesthetics technology, Aesthetics Biomedical's brand is committed to creation, distribution and marketing of novel aesthetic devices, products and services.
  • Vivace Ultra, the next generation and future of personalized aesthetics, has cleared the United States Food and Drug Administration (FDA) intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
  • In addition, this technology offers four unique delay speeds for optimal time pulses as well as the ability to toggle radiofrequency on or off.
  • About Aesthetics Biomedical Inc.: Headquartered in Phoenix, AZ., Aesthetics Biomedical is committed to the development and distribution of novel aesthetic devices, products and services in the global market.

NaturalShrimp Announces Filing of Joint Patent Application

Retrieved on: 
Thursday, October 6, 2022
Risk, Efficiency, Annual report, Intellectual property, Aquaculture, Collaboration, RAS, Technology, Company, OTCQB, CEO, IP, Patent, GLOBE, EC, Forward-looking statement, Terminology, Engineering, Intellectual property protection in consumer electronics industry, Hydrolastic, Electrocoagulation

DALLAS, TX, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), and its technology partner, Hydrenesis, Inc., today announced the filing a United States joint patent application to further strengthen the Intellectual

Key Points: 
  • The newly filed patent application involves technology co-developed by NaturalShrimp and Hydrenesis as a strategy to augment existing IP protection with additional, and more advanced methods and apparatus.
  • NaturalShrimp will license the EC and HydroGas technologies for various aquatic species.
  • This joint patent represents more than 12 months of collaboration and is expected to add shareholder value as the commercialization phases unfold.
  • NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa.

NaturalShrimp Partners With Leading Foodservice Distributor

Retrieved on: 
Wednesday, September 28, 2022
VP, Health, Immersion, Rest, Risk, US Foods, OTCQB, Company, Partnership, Industry, RAS, Program, Forward-looking statement, Technology, Terminology, Electrocoagulation, Annual report, Restaurant, GLOBE, Hydrolastic, Marketing, Aquaculture, Regulation of tobacco by the U.S. Food and Drug Administration

US Foods is one of Americas great food companies and a leading foodservice distributor, partnering with approximately 250,000 restaurants and foodservice operators to help their businesses succeed.

Key Points: 
  • US Foods is one of Americas great food companies and a leading foodservice distributor, partnering with approximately 250,000 restaurants and foodservice operators to help their businesses succeed.
  • We are very excited to build this channel-specific program for a leading national distributor, said Marco van den Berg, VP of Sales and Marketing.
  • NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa.
  • NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.

NaturalShrimp Issues Updates on Florida Expansion and La Coste Fire

Retrieved on: 
Monday, August 8, 2022
Risk, CEO, Forward-looking statement, GLOBE, Recirculating aquaculture system, EC, Growth, RAS, Electrocoagulation, Lacoste, Company, OTCQB, Workforce, Fire marshal, Goal, Château de La Coste (Lot), WTP, Terminology, Aquaculture, Risk management

The Fire Marshall report stated the fire that damaged the La Coste, TX Water Treatment Plant (WTP) was caused by electrical arcing in the electrical distribution equipment to the building.

Key Points: 
  • The Fire Marshall report stated the fire that damaged the La Coste, TX Water Treatment Plant (WTP) was caused by electrical arcing in the electrical distribution equipment to the building.
  • Clearing the land required to construct the inland 36,000 pound per week shrimp production facility in Jefferson County, Florida has been completed.
  • This expansion site will allow us to showcase a highly scalable, capital-efficient new facility to meet increasing long-term growth targets.
  • Demonstrating effective scaling of production output to meet predicated growth in demand will add value for NaturalShrimp as it enters an expansive Florida market, concluded Easterling.

NaturalShrimp Issues Iowa and Texas Production Updates

Retrieved on: 
Thursday, August 4, 2022
PL, Risk, CEO, Forward-looking statement, GLOBE, Recirculating aquaculture system, Growth, EC, RAS, Electrocoagulation, Company, Water treatment, OTCQB, WTP, Terminology, Aquaculture

The retrofit has mainly included replacing the previous tank biofiltration with NaturalShrimp technology and upgrading the tank heating system.

Key Points: 
  • The retrofit has mainly included replacing the previous tank biofiltration with NaturalShrimp technology and upgrading the tank heating system.
  • The hatchery will allow the Company to control the postlarvae (PL) supply while lowering the PL cost for not only the Iowa grow out facilities, but also for the other NaturalShrimp production facilities.
  • The Company expects that production will increase each month reaching a weekly production of 6,000 pounds during the first quarter of 2023.
  • NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa.

NaturalShrimp Issues Shareholder Letter and Provides Corporate Update

Retrieved on: 
Tuesday, July 5, 2022
Water, Investor relations, OTCQB, CEO, Electrocoagulation, Microalgae, Pleasure, EC, Engineering, Nitrogen, DALLAS, GLOBE, Spice, Salmon, ERT, Commerce, Company, Aquaculture, Incident response team, Terminology, Probiotic, Filtration, RAS, Risk, Lacoste, Technology, Dallas–Fort Worth metroplex, Chamber of commerce, Recirculating aquaculture system, Health, Château de La Coste (Lot), NASDAQ, E. A. Fairbairn Water Treatment Plant, WTP, Hydrolastic, Forward-looking statement, Conference

No one was hurt and this did not cause any damage to the main production building containing the shrimp.

Key Points: 
  • No one was hurt and this did not cause any damage to the main production building containing the shrimp.
  • The virtually untapped live market within the United States provides a greater profit margin than the fresh, refrigerated shrimp retail market at this time.
  • We are committed to establishing a NaturalShrimp Outlet and have identified a location of interest in the Dallas Fort Worth area.
  • We are pleased to announce that Chef Douwe Iedema will be heading up our NaturalShrimp Outlet along with offering his unique NaturalShrimp sauces and spices.